By Christian Moess Laursen

AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of so-called progression-free survival in patients.

The Anglo-Swedish pharma giant said Friday the drug--fully-named datopotamab deruxtecan--showed a statistical significant and clinically meaningful improvement compared with chemotherapy in patients with breast cancer.

The safety profile of the treatment was consistent with previous clinical trials in breast cancer with no new safety signals identified, it said.

Progression-free survival means the length of time during and after treatment of a disease, such as cancer, a patient lives with the disease without it getting worse.

Dato-DXd is being jointly-developed with Japan's Daiichi Sankyo.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

September 22, 2023 02:38 ET (06:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Daiichi Sankyo (PK) Charts.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Daiichi Sankyo (PK) Charts.